Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Aciclovir/Loxoprofen/Valaciclovir

Encephalopathy and renal dysfunction

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Unita R, et al. A decreasing plasma concentration of a toxicologically active metabolite 9-carboxymethoxymethylguanine after dialysis - A potential new clinical biomarker for improving encephalopathy in patients treated with acyclovir. Journal of Infection and Chemotherapy 29 : 1068-1070, No. 11, Nov 2023. Available from: URL: https://dx.doi.org/10.1016/j.jiac.2023.07.001 Unita R, et al. A decreasing plasma concentration of a toxicologically active metabolite 9-carboxymethoxymethylguanine after dialysis - A potential new clinical biomarker for improving encephalopathy in patients treated with acyclovir. Journal of Infection and Chemotherapy 29 : 1068-1070, No. 11, Nov 2023. Available from: URL: https://dx.doi.org/10.1016/j.jiac.2023.07.001
Metadaten
Titel
Aciclovir/Loxoprofen/Valaciclovir
Encephalopathy and renal dysfunction
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56655-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Tretinoin

Case report

Propranolol

Case report

Remdesivir

Case report

Tozinameran

Case report

Tozinameran

Case report

Empagliflozin